Literature DB >> 12464480

Enzymatic debridement of burn wound with collagenase in children with partial-thickness burns.

Coşkun Ozcan1, Orkan Ergün, Ahmet Celik, Nergül Cördük, Geylani Ozok.   

Abstract

Seventy-eight pediatric burn patients treated by enzymatic debridement with collagenase clostridiopeptidase A (CCA), were compared to 41 patients those burn wounds were excised surgically. Patients whose burn wounds were initially assessed as partial-thickness at admission were enrolled in the study. Total removal of eschar was achieved in 49 of 78 (62.8%) patients by CCA only (group D). In 29 patients (37.2%), therapy with CCA was ceased because of the development of burn wound infection or a manifest need for grafting of the wound, therefore, these patients underwent tangential wound excision (group DS). The records of 41 patients, treated by early tangential excision, having similar burn wounds by extent and depth with groups D and DS were used as controls (group S). There was no significant difference between the time to achieve a clean wound bed in groups D, DS and S (mean 7.8, 8, and 7 days, respectively, P>0.05). In group D, none of the patients required blood transfusion, except one. Patients in group DS were found to have fewer excisions (mean 1.1) when compared to those in group S (mean 1.5, P<0.05). The shortest hospital stay was found in group D (12.5 days, P<0.01). In conclusion, the use of CCA, provided a short hospital stay, reduced the overall need for surgery and blood transfusions in patients with partial-thickness burns. Thus, CCA should be considered as an initial treatment of choice for removal of eschar in children, having a partial-thickness burn wound without infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464480     DOI: 10.1016/s0305-4179(02)00191-2

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  9 in total

Review 1.  A general overview of burn care.

Authors:  Michel H E Hermans
Journal:  Int Wound J       Date:  2005-09       Impact factor: 3.315

2.  Bromelain-based enzymatic debridement and minimal invasive modality (mim) care of deeply burned hands.

Authors:  Y Krieger; G Rubin; A Schulz; N Rosenberg; A Levi; A J Singer; L Rosenberg; Y Shoham
Journal:  Ann Burns Fire Disasters       Date:  2017-09-30

3.  Rapid enzymatic burn debridement: A review of the paediatric clinical trial experience.

Authors:  Yaron Shoham; Yuval Krieger; Guy Rubin; Ingo Koenigs; Bernd Hartmann; Frank Sander; Alexandra Schulz; Keren David; Lior Rosenberg; Eldad Silberstein
Journal:  Int Wound J       Date:  2020-05-22       Impact factor: 3.315

4.  Collagenase for Wound Debridement in the Neonatal Intensive Care Unit: A Retrospective Case Series.

Authors:  Elizabeth Huett; Whitney Bartley; Darla Morris; Della Reasbeck; Beth McKitrick-Bandy; Charlotte Yates
Journal:  Pediatr Dermatol       Date:  2017-05       Impact factor: 1.588

Review 5.  Digesting a Path Forward: The Utility of Collagenase Tumor Treatment for Improved Drug Delivery.

Authors:  Aaron Dolor; Francis C Szoka
Journal:  Mol Pharm       Date:  2018-05-16       Impact factor: 4.939

6.  Wound healing of cutaneous sulfur mustard injuries: strategies for the development of improved therapies.

Authors:  John S Graham; Robert P Chilcott; Paul Rice; Stephen M Milner; Charles G Hurst; Beverly I Maliner
Journal:  J Burns Wounds       Date:  2005-01-05

7.  Collagenase promotes the cellular responses to injury and wound healing in vivo.

Authors:  Kathleen N Riley; Ira M Herman
Journal:  J Burns Wounds       Date:  2005-05-17

8.  Effects of topical Kiwifruit on healing of neuropathic diabetic foot ulcer.

Authors:  Gholamreza Mohajeri; Masumeh Safaee; Mohamad Hossein Sanei
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

Review 9.  Towards extracellular matrix normalization for improved treatment of solid tumors.

Authors:  Hoda Soleymani Abyaneh; Maximilian Regenold; Trevor D McKee; Christine Allen; Marc A Gauthier
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.